» Articles » PMID: 34673755

Immunogenicity and Efficacy of          heterologous ChAdOx1-BNT162b2 Vaccination

Abstract

Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine, European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 vaccine as a booster. However, the effectiveness and the immunogenicity of this vaccination regimen have not been formally tested. Here we show that the heterologous ChAdOx1-S-nCoV-19 and BNT162b2 combination confers better protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than the homologous BNT162b2 and BNT162b2 combination in a real-world observational study of healthcare workers (n = 13,121). To understand the underlying mechanism, we conducted a longitudinal survey of the anti-spike immunity conferred by each vaccine combination. Both combinations induced strong anti-spike antibody responses, but sera from heterologous vaccinated individuals displayed a stronger neutralizing activity regardless of the SARS-CoV-2 variant. This enhanced neutralizing potential correlated with increased frequencies of switched and activated memory B cells that recognize the SARS-CoV-2 receptor binding domain. The ChAdOx1-S-nCoV-19 vaccine induced a weaker IgG response but a stronger T cell response than the BNT162b2 vaccine after the priming dose, which could explain the complementarity of both vaccines when used in combination. The heterologous vaccination regimen could therefore be particularly suitable for immunocompromised individuals.

Citing Articles

An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4 T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis.

Lukeman H, Al-Wassiti H, Fabb S, Lim L, Wang T, Britton W EBioMedicine. 2025; 113:105599.

PMID: 39955975 PMC: 11871481. DOI: 10.1016/j.ebiom.2025.105599.


Mechanistic models of humoral kinetics following COVID-19 vaccination.

Stocks D, Thomas A, Finn A, Danon L, Brooks-Pollock E J R Soc Interface. 2025; 22(222):20240445.

PMID: 39876790 PMC: 11775660. DOI: 10.1098/rsif.2024.0445.


Neutralizing antibodies and safety of a COVID-19 vaccine against SARS-CoV-2 wild-type and Omicron variants in solid cancer patients.

Chewaskulyong B, Satjaritanun P, Ketpueak T, Suksombooncharoen T, Charoentum C, Nuchpong N PLoS One. 2024; 19(11):e0310781.

PMID: 39509358 PMC: 11542819. DOI: 10.1371/journal.pone.0310781.


Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.

Habibi M, Ahmadpour S, Tafaroji J, Eazi S, Mineaie P, Minaee P Curr Drug Targets. 2024; 26(2):73-87.

PMID: 39318005 DOI: 10.2174/0113894501323529240910015912.


Assessment of immune responses to a Comirnaty® booster following CoronaVac® vaccination in healthcare workers.

Bochnia-Bueno L, Coelho G, Cataneo A, Zanluca C, Ferreira L, Cavalcanti L Mem Inst Oswaldo Cruz. 2024; 119:e230239.

PMID: 39258622 PMC: 11385826. DOI: 10.1590/0074-02760230239.